Format

Send to

Choose Destination
Diagn Microbiol Infect Dis. 2015 Sep;83(1):53-5. doi: 10.1016/j.diagmicrobio.2015.04.012. Epub 2015 May 1.

Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.

Author information

1
Center for Anti-Infective Research & Development, Hartford Hospital, Hartford, CT, USA. Electronic address: joseph.kuti@hhchealth.org.
2
Riley Hospital for Children, Indianapolis, IN, USA.
3
Columbia University, New York, NY, USA.
4
St Christopher's Hospital for Children, Philadelphia, PA, USA.
5
CT Children's Medical Center, Hartford, CT, USA.
6
University of North Carolina, Chapel Hill, NC, USA.
7
Nationwide Children's Hospital, Columbus, OH, USA.
8
Children's Medical Center, Dallas, TX, USA.
9
Center for Anti-Infective Research & Development, Hartford Hospital, Hartford, CT, USA.

Abstract

The activity of ceftolozane/tazobactam was tested against 50 nonduplicate Pseudomonas aeruginosa from 18 cystic fibrosis children collected in 2012-2014. These isolates were multidrug resistant with susceptibility to meropenem, ceftazidime, and piperacillin/tazobactam of 46%, 58%, and 50%, respectively. Ceftolozane/tazobactam was the most active with MIC50, MIC90, and percent susceptibility of 2mg/L, 8 mg/L, and 86%.

KEYWORDS:

Antibiotic; Beta-lactam; Cystic fibrosis; Pseudomonas; Susceptibility

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center